Sepsis - Pipeline Review, H1 2017

Publisher Name :
Date: 28-Feb-2017
No. of pages: 278
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2017, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 6, 1, 60, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 7 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Sepsis - Pipeline Review, H1 2017

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Sepsis - Overview 10
Sepsis - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 17
Products under Development by Companies 20
Products under Development by Universities/Institutes 25
Sepsis - Therapeutics Assessment 28
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Sepsis - Companies Involved in Therapeutics Development 38
Adrenomed AG 38
Altor BioScience Corp 38
Am-Pharma BV 39
Arch Biopartners Inc. 39
Aridis Pharmaceuticals LLC 40
Asahi Kasei Pharma Corp 40
Astellas Pharma Inc 41
Batu Biologics Inc 41
Biomedica Management Corp 42
Boehringer Ingelheim GmbH 42
Bristol-Myers Squibb Company 43
Cell2B Advanced Therapeutics SA 43
Chiome Bioscience Inc 44
Cilian AG 44
Dr. Franz Kohler Chemie GmbH 45
Endacea Inc 45
Evec Inc 46
Ferring International Center SA 46
Huons Co Ltd 47
Immune Response BioPharma Inc 47
Immunethep SA 48
InflaRx GmbH 48
Inotrem SA 49
Integrated BioTherapeutics Inc 49
Lead Discovery Center GmbH 50
Leading BioSciences Inc 50
Lixte Biotechnology Holdings Inc 51
Merck & Co Inc 51
Navigen Pharmaceuticals Inc 52
Nohla Therapeutics Inc 52
Novartis AG 53
OncoImmune Inc 53
Ono Pharmaceutical Co Ltd 54
Opsona Therapeutics Ltd 54
Peptinov SAS 55
ProThera Biologics Inc 55
Ra Pharmaceuticals Inc 56
Recce Ltd 56
Revimmune LLC 57
Ribomic Inc 57
SciClone Pharmaceuticals Inc 58
SetLance srl 58
Shionogi & Co Ltd 59
Silence Therapeutics Plc 59
SK Biopharmaceuticals Co Ltd 60
Spider Biotech 60
Stemedica Cell Technologies Inc 61
Syntiron LLC 61
TaiRx Inc 62
Takeda Pharmaceutical Company Ltd 62
Therakind Ltd 63
Therashock LLC 63
TiGenix NV 64
VBS Pharmaceuticals 64
Sepsis - Drug Profiles 65
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 65
3K3A-APC - Drug Profile 66
7-H9 - Drug Profile 68
AB-012 - Drug Profile 69
AB-022 - Drug Profile 70
AcPepA - Drug Profile 71
adrecizumab - Drug Profile 72
ALT-836 - Drug Profile 73
AM-12 - Drug Profile 75
AM/AMBP-1 - Drug Profile 76
Aspidasept - Drug Profile 77
Atu-111 - Drug Profile 78
AyuV-25 - Drug Profile 79
BC-1215 - Drug Profile 80
BI-113823 - Drug Profile 81
Biologic to Inhibit PD-L1 for Immunology - Drug Profile 82
BMS-936559 - Drug Profile 83
BMS-986189 - Drug Profile 86
BRL-44408 - Drug Profile 87
C-23 - Drug Profile 88
CAR Peptide - Drug Profile 89
cefiderocol - Drug Profile 90
ceftaroline fosamil - Drug Profile 92
Cell Therapy for Sepsis - Drug Profile 95
Cx-611 - Drug Profile 96
CYT-107 - Drug Profile 100
Drug for Sepsis and Septic Shock - Drug Profile 103
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 104
EC-18 - Drug Profile 105
Escherichia coli vaccine - Drug Profile 107
ethinylestradiol - Drug Profile 108
EV-007156 - Drug Profile 109
Gamma-PN - Drug Profile 110
Glyco-23 - Drug Profile 111
HBN-1 - Drug Profile 112
HBN-3 - Drug Profile 113
HBN-4 - Drug Profile 114
HU-003 - Drug Profile 115
IFX-1 - Drug Profile 116
ImmStem - Drug Profile 118
ImmuneSafe - Drug Profile 119
IMT-504 - Drug Profile 120
IR-999 - Drug Profile 122
Klebsiella pneumoniae vaccine - Drug Profile 123
L-257 - Drug Profile 124
L-971 - Drug Profile 125
LB-100 - Drug Profile 127
lodelcizumab - Drug Profile 130
M-33 - Drug Profile 131
M-6229 - Drug Profile 133
melatonin - Drug Profile 134
Metablok - Drug Profile 135
Monoclonal Antibodies for Sepsis - Drug Profile 136
Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile 137
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 138
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 139
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 140
Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile 141
Monoclonal Antibody to Inhibit Semaphorin 3A for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 142
Motrem - Drug Profile 143
MSP-68 - Drug Profile 144
NAV-838 - Drug Profile 145
nivolumab - Drug Profile 146
NOXD-21 - Drug Profile 185
OPN-305 - Drug Profile 186
OTP-300 - Drug Profile 189
OTP-602 - Drug Profile 190
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 191
physostigmine salicylate - Drug Profile 192
pneumococcal vaccine - Drug Profile 193
PNV-1 - Drug Profile 194
Protein to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 195
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 196
R-190 - Drug Profile 198
RA-101295 - Drug Profile 200
RBM-005 - Drug Profile 201
RECCE-327 - Drug Profile 202
Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile 204
Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile 205
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 209
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 210
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 211
Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile 212
Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 213
Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 214
Recombinant Protein to Target Von Willebrand Factor Type A1 Domain for Sepsis - Drug Profile 215
SAN-101 - Drug Profile 216
SB-056 - Drug Profile 217
selepressin - Drug Profile 218
Slit-2N - Drug Profile 219
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 221
Small Molecule to HDAC6 for Sepsis - Drug Profile 222
Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 223
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 224
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 225
Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 226
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 227
Small Molecules to Inhibit Sialidase for Bacterial Sepsis - Drug Profile 228
SP-14 - Drug Profile 229
SP-9 - Drug Profile 230
Staphylococcus aureus (multivalent) vaccine - Drug Profile 231
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 232
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 234
Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 240
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 241
Synthetic Peptides for Infectious Disease - Drug Profile 242
Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 243
Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 244
TF-0003 - Drug Profile 245
thrombomodulin alfa - Drug Profile 246
thymalfasin - Drug Profile 248
tosatoxumab - Drug Profile 249
tranexamic acid - Drug Profile 251
TRX-306 - Drug Profile 253
vancomycin hydrochloride - Drug Profile 254
Yersinia pestis vaccine - Drug Profile 255
Sepsis - Dormant Projects 256
Sepsis - Discontinued Products 260
Sepsis - Product Development Milestones 262
Featured News & Press Releases 262
Appendix 269
Methodology 269
Coverage 269
Secondary Research 269
Primary Research 269
Expert Panel Validation 269
Contact Us 269
Disclaimer 270

List of Tables

Number of Products under Development for Sepsis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Sepsis - Pipeline by Adrenomed AG, H1 2017
Sepsis - Pipeline by Altor BioScience Corp, H1 2017
Sepsis - Pipeline by Am-Pharma BV, H1 2017
Sepsis - Pipeline by Arch Biopartners Inc., H1 2017
Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Sepsis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Sepsis - Pipeline by Astellas Pharma Inc, H1 2017
Sepsis - Pipeline by Batu Biologics Inc, H1 2017
Sepsis - Pipeline by Biomedica Management Corp, H1 2017
Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Sepsis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
Sepsis - Pipeline by Chiome Bioscience Inc, H1 2017
Sepsis - Pipeline by Cilian AG, H1 2017
Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H1 2017
Sepsis - Pipeline by Endacea Inc, H1 2017
Sepsis - Pipeline by Evec Inc, H1 2017
Sepsis - Pipeline by Ferring International Center SA, H1 2017
Sepsis - Pipeline by Huons Co Ltd, H1 2017
Sepsis - Pipeline by Immune Response BioPharma Inc, H1 2017
Sepsis - Pipeline by Immunethep SA, H1 2017
Sepsis - Pipeline by InflaRx GmbH, H1 2017
Sepsis - Pipeline by Inotrem SA, H1 2017
Sepsis - Pipeline by Integrated BioTherapeutics Inc, H1 2017
Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2017
Sepsis - Pipeline by Leading BioSciences Inc, H1 2017
Sepsis - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Sepsis - Pipeline by Merck & Co Inc, H1 2017
Sepsis - Pipeline by Navigen Pharmaceuticals Inc, H1 2017
Sepsis - Pipeline by Nohla Therapeutics Inc, H1 2017
Sepsis - Pipeline by Novartis AG, H1 2017
Sepsis - Pipeline by OncoImmune Inc, H1 2017
Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Sepsis - Pipeline by Opsona Therapeutics Ltd, H1 2017
Sepsis - Pipeline by Peptinov SAS, H1 2017
Sepsis - Pipeline by ProThera Biologics Inc, H1 2017
Sepsis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
Sepsis - Pipeline by Recce Ltd, H1 2017
Sepsis - Pipeline by Revimmune LLC, H1 2017
Sepsis - Pipeline by Ribomic Inc, H1 2017
Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H1 2017
Sepsis - Pipeline by SetLance srl, H1 2017
Sepsis - Pipeline by Shionogi & Co Ltd, H1 2017
Sepsis - Pipeline by Silence Therapeutics Plc, H1 2017
Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Sepsis - Pipeline by Spider Biotech, H1 2017
Sepsis - Pipeline by Stemedica Cell Technologies Inc, H1 2017
Sepsis - Pipeline by Syntiron LLC, H1 2017
Sepsis - Pipeline by TaiRx Inc, H1 2017
Sepsis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Sepsis - Pipeline by Therakind Ltd, H1 2017
Sepsis - Pipeline by Therashock LLC, H1 2017
Sepsis - Pipeline by TiGenix NV, H1 2017
Sepsis - Pipeline by VBS Pharmaceuticals, H1 2017
Sepsis - Dormant Projects, H1 2017
Sepsis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Sepsis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Sepsis - Dormant Projects, H1 2017 (Contd..3), H1 2017
Sepsis - Discontinued Products, H1 2017
Sepsis - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

Number of Products under Development for Sepsis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia-Pacific Niclosamide Market Report 2017
    Published: 26-Apr-2017        Price: US 4000 Onwards        Pages: 105
    In this report, the Asia-Pacific Niclosamide market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (Kg), revenue (Million USD), market share and growth rate of Niclosamide for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Korea - Taiwan ......
  • Cephalosporin Industry Forecasts - China Focus
    Published: 17-Apr-2017        Price: US 1800 Onwards        Pages: 135
    This study focuses on China's Cephalosporin industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The C......
  • Penicillin Industry Forecasts - China Focus
    Published: 17-Apr-2017        Price: US 1800 Onwards        Pages: 85
    This study focuses on China's Penicillin industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The Chin......
  • Penicillin Markets in China
    Published: 17-Apr-2017        Price: US 4000 Onwards        Pages: 216
    China's demand for Penicillin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry s......
  • Cephalosporin Companies in China
    Published: 17-Apr-2017        Price: US 1800 Onwards        Pages: 59
    This study focuses on China's Cephalosporin industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of go......
  • Penicillin Companies in China
    Published: 17-Apr-2017        Price: US 1800 Onwards        Pages: 77
    This study focuses on China's Penicillin industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods......
  • Cephalosporin Markets in China
    Published: 17-Apr-2017        Price: US 4000 Onwards        Pages: 270
    China's demand for Cephalosporin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industr......
  • United States Cytomegalovirus Therapeutics Market Report 2017
    Published: 03-Apr-2017        Price: US 3800 Onwards        Pages: 104
    In this report, the United States Cytomegalovirus Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and gr......
  • Global Antibiotics Partnering Terms and Agreements 2010 to 2017
    Published: 01-Apr-2017        Price: US 2995 Onwards        Pages: 222
    Summary The Global Antibiotics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the antibiotic partnering deals and agreements entered into by the worlds leading healthcare companies The Global Antibiotics Partnering Terms and Agreements 2010 to 2017 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs